ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,0724
0,00%
Bitcoin
63.746,57
1,36%
Brent Oil
82,765
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cellectar Biosciences Inc (CLRBW)

  7. Cellectar Biosciences Inc (CLRBW) Notícias

CLRBW

Cellectar Biosciences (CLRBW)

Cellectar Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CLRBW
DataHoraFonteTítuloCódigoCompanhia
07/01/201911:30GlobeNewswire Inc.Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple MyelomaNASDAQ:CLRBWCellectar Biosciences Inc
03/01/201911:30GlobeNewswire Inc.Cellectar Biosciences to Present at the Biotech ShowcaseNASDAQ:CLRBWCellectar Biosciences Inc
11/12/201811:30GlobeNewswire Inc.Cellectar Granted Japanese Patent for CLR 131NASDAQ:CLRBWCellectar Biosciences Inc
04/12/201811:30GlobeNewswire Inc.Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple MyelomaNASDAQ:CLRBWCellectar Biosciences Inc
13/11/201811:30GlobeNewswire Inc.Cellectar Reports Third Quarter 2018 Financial Results and Provides Business UpdateNASDAQ:CLRBWCellectar Biosciences Inc
12/11/201811:30GlobeNewswire Inc.Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology StudiesNASDAQ:CLRBWCellectar Biosciences Inc
02/10/201809:00GlobeNewswire Inc.Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myelo...NASDAQ:CLRBWCellectar Biosciences Inc
27/09/201809:30GlobeNewswire Inc.Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare ConferenceNASDAQ:CLRBWCellectar Biosciences Inc
25/09/201809:30GlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric OsteosarcomaNASDAQ:CLRBWCellectar Biosciences Inc
24/09/201809:00GlobeNewswire Inc.Cellectar Biosciences Provides an Update on the FDA Import AlertNASDAQ:CLRBWCellectar Biosciences Inc
17/09/201809:30GlobeNewswire Inc.FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of OsteosarcomaNASDAQ:CLRBWCellectar Biosciences Inc
29/08/201809:30GlobeNewswire Inc.Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:CLRBWCellectar Biosciences Inc
20/08/201809:30GlobeNewswire Inc.Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma PatientsNASDAQ:CLRBWCellectar Biosciences Inc
13/08/201809:00GlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s SarcomaNASDAQ:CLRBWCellectar Biosciences Inc
10/08/201809:00GlobeNewswire Inc.Cellectar Reports 2018 Second Quarter Financial Results and Provides Business UpdateNASDAQ:CLRBWCellectar Biosciences Inc
01/08/201809:30GlobeNewswire Inc.Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug ConjugateNASDAQ:CLRBWCellectar Biosciences Inc
31/07/201817:05GlobeNewswire Inc.Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Op...NASDAQ:CLRBWCellectar Biosciences Inc
27/07/201809:30GlobeNewswire Inc.Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering NASDAQ:CLRBWCellectar Biosciences Inc
18/07/201809:00GlobeNewswire Inc.Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL PatientsNASDAQ:CLRBWCellectar Biosciences Inc
17/07/201809:00GlobeNewswire Inc.Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical ...NASDAQ:CLRBWCellectar Biosciences Inc
13/07/201817:05GlobeNewswire Inc.Cellectar Announces 1-for-10 Reverse Stock SplitNASDAQ:CLRBWCellectar Biosciences Inc
09/07/201809:00GlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s SarcomaNASDAQ:CLRBWCellectar Biosciences Inc
28/06/201809:00GlobeNewswire Inc.Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 TrialNASDAQ:CLRBWCellectar Biosciences Inc
07/06/201809:30GlobeNewswire Inc.Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131NASDAQ:CLRBWCellectar Biosciences Inc
06/06/201809:00GlobeNewswire Inc.FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of RhabdomyosarcomaNASDAQ:CLRBWCellectar Biosciences Inc
11/05/201809:00GlobeNewswire Inc.Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial ResultsNASDAQ:CLRBWCellectar Biosciences Inc
09/05/201815:28GlobeNewswire Inc.Cellectar Granted Orphan Drug Designation for CLR 131 to Treat RhabdomyosarcomaNASDAQ:CLRBWCellectar Biosciences Inc
02/05/201809:00GlobeNewswire Inc.Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat NeuroblastomaNASDAQ:CLRBWCellectar Biosciences Inc
17/04/201809:00GlobeNewswire Inc.Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Mu...NASDAQ:CLRBWCellectar Biosciences Inc
16/04/201809:05GlobeNewswire Inc.Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broa...NASDAQ:CLRBWCellectar Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CLRBW

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HOOT4
HOTEIS OTHON PN
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
BOV
ZAMP3
Zamp ON
BOV
TPIS3
TRIUNFO PART ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados